1,885 results on '"Vose, Julie M."'
Search Results
2. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
3. MiR-17∼92 is involved in NF-κB activation via targeting the ubiquitin-editing proteins to mediate RIP1 complex polyubiquitinations in ABC-DLBCL
4. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
5. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
6. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
7. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
8. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
9. Benchmarks for Academic Oncology Faculty.
10. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
11. Data from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
12. Table S2 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
13. Supplementary Methods from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
14. Figure S4 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
15. FIGURE 3 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
16. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia
17. FIGURE 4 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
18. FIGURE 5 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
19. FIGURE 1 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
20. FIGURE 6 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
21. FIGURE 2 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
22. Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects
23. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
24. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
25. Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience
26. Complementary and Alternative Medicine in Cancer Care: Does It Have a Role?
27. Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
28. MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications
29. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project
30. Electronic Medical Records and Physicians: A Love-Hate Relationship
31. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
32. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
33. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
34. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma
35. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
36. Diagnosis and Treatment of Non-Hodgkin’s Lymphoma of Adults
37. 2023 Year in Review: Topics in Hematology/Oncology
38. Multidisciplinary Team Approach Is Integral to Oncology Care
39. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
40. CLL-217 Patient Characteristics and Time to Next Treatment With Ibrutinib and Anti-CD20 Monotherapy as First-Line Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
41. Non-Hodgkin's lymphomas, version 4.2014.
42. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
43. 171 - Non-Hodgkin Lymphomas
44. An International Real-World Analysis of Relapsed/Refractory Lymphoma Occurring During Pregnancy
45. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma
46. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network
47. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
48. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐ H odgkin lymphoma: A phase I/ II study
49. ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology
50. Abstract 6396: BET inhibition alleviates T-cell dysfunction in chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.